Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106340 · ClinicalTrials.gov registry record · Phase 3
Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,118
- Enrollment target
NCT00106340: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00106340 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 3,118 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (304% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00106340, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,118 participants
- Enrollment target
Study Summary
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of glimepiride in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.
Interventions
- DRUG Metformin
- DRUG vildagliptin
- DRUG glimepiride
- DRUG Vildagliptin matching placebo
- DRUG Glimepiride matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,118 participants |
| Start Date | 2005-03 |
| Est. Completion | 2008-05-20 |
| Phase | Phase 3 |
What the finished NCT00106340 record still lists
NCT00106340 is an interventional study that assigns participants to a tested intervention. Its 3,118 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (304% higher).
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT00106340 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00106340 about?
NCT00106340 is a clinical study titled "Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes". Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of glimepiride in lowering overall blood glucose levels whe...
What is the current status of trial NCT00106340?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,118 participants. The study started on 2005-03. Estimated completion is 2008-05-20.
What interventions are being tested in trial NCT00106340?
The interventions under investigation include: Metformin (DRUG), vildagliptin (DRUG), glimepiride (DRUG), Vildagliptin matching placebo (DRUG), Glimepiride matching placebo (DRUG).
Who is sponsoring clinical trial NCT00106340?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00106340's enrollment target sits among peer trials
3,118 76th of 2000 higher than 1,925 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05051722 · 3,110 participants
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- NCT04722822 · 3,100 participants · NA
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
- NCT06224205 · 3,150 participants · NA
Digital Detection of Dementia (D Cubed) Studies: D3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia